中东和非洲先天性遗传性视神经萎缩市场报告 - 行业趋势和预测至2029年

中东和非洲莱伯先天性黑蒙市场，按疾病类型（婴儿型、青少年型和其他）、类型（治疗和诊断）、最终用户（医院、专科诊所、门诊手术中心、家庭医疗保健和其他）、分销渠道（直接招标和零售销售）行业趋势和预测到 2029 年。

市场分析和见解

中东和非洲莱伯先天性黑蒙市场受到多种因素的推动，例如糖尿病和胃肠道疾病等慢性病的患病率增加、新兴参与者的数量不断增加以及输液泵家庭护理服务的普及，这些因素增加了市场需求，此外，研发投资的增加也推动了市场增长。目前，正在进行各种研究，预计这将为制造商创造竞争优势，以开发新的创新型莱伯先天性黑蒙治疗方法和疗法，预计这将为莱伯先天性黑蒙市场提供各种其他机会。然而，政府对输液治疗期间的审批和设备错误的严格规定预计将阻碍增长。

莱伯先天性黑蒙症市场

中东和非洲莱伯先天性黑蒙市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息，分析了新兴收入来源、市场法规变化、产品批准、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情景，请联系我们获取分析师简报，我们的团队将帮助您创建收入影响解决方案，以实现您的预期目标，由于保证付款和产品国际销量高，客户偏好度不断提高是推动预测期内市场需求的主要驱动因素。

中东和非洲莱伯先天性黑蒙市场支持并旨在减少疾病的进展。Data Bridge Market Research 分析，在 2022 年至 2029 年的预测期内，中东和非洲莱伯先天性黑蒙市场将以 2.7% 的复合年增长率增长。

报告指标	细节
预测期	2022 至 2029 年
基准年	2021
历史岁月	2020（可定制至 2019 - 2014）
定量单位	收入（百万美元），定价（美元）
涵盖的领域	按疾病类型（婴儿型、青少年型及其他）、类型（治疗、诊断）、最终用户（医院、专科诊所、门诊手术中心、家庭医疗保健及其他）、分销渠道（直接招标和零售）
覆盖国家	按国家/地区（沙特阿拉伯、南非、阿联酋、以色列、科威特、埃及、中东和非洲其他地区）
涵盖的市场参与者	Invitae Corporation、Spark Therapeutics, Inc.、LKC Technologies、CENTOGENE NV、Optos、Metrovision、Blue Print Genetics Oy（Quest Diagnostics 的子公司）、CD Genomics、ProQR Therapeutics、OCUGEN, INC.、MeiraGTx Limited、Coave Therapeutics、IVERIC bio, Inc.、Atsena Therapeutics、Editas Medicine、Eluminex Biosciences、Okuvision、Astellas Pharma Inc.、Allergan、agtc、Gyroscope Therapeutics Limited、SparingVision、Kubota Pharmaceutical Holdings Co. Ltd.、REGENXBIO Inc. 等。

中东和非洲莱伯先天性黑蒙症市场动态

驱动程序

rpe65基因介导的视网膜疾病发病率和患病率增加

遗传性视网膜营养不良 (IRD) 是一组遗传多样性的渐进性视力丧失疾病。由于 65 kDa 视网膜色素上皮 (RPE65) 基因的双等位基因突变导致 IRD 而导致视力丧失的成人和儿童患者通常在临床上被诊断为视网膜色素变性 (RP) 和莱伯先天性黑蒙 (LCA)。

莱伯先天性黑蒙 (LCA) 是一种主要影响视网膜的眼部疾病。LCA 的特征是出生或出生后头几个月出现严重的视力障碍、眼球四处乱转或眼球震颤、瞳孔对光反应差、眼球指征（戳、揉和/或按压眼睛）以及全视野视网膜电图 (ERG) 无法检测或严重异常。LCA 通常是一种常染色体隐性遗传病。

增加产品线和临床试验

遗传性视网膜疾病和莱伯先天性黑蒙症治疗的持续创新有可能对市场产生积极影响，因为当这些产品获得市场批准时，市场规模将会增加。由于 LCA 没有药物治疗，主要的市场参与者正在不断创新治疗方法或投资于治疗方法的研发。世界各地正在招募各种正在进行的临床试验，以寻找疾病的治疗机制。

机会

政府加大力度应对莱伯氏先天性黑蒙症

据世界卫生组织统计，单基因IRD的发病率约为每4万名新生儿中就有1名患有此病。为了预防此类疾病，全球多个国家的政府都采取了行动。

世界各国政府为给本国人民提供最好的治疗而采取的各种计划和决定是预计会增加需求的主要因素，并将为莱伯先天性黑蒙市场带来机遇。

限制/挑战

产品成本是市场的主要因素。在遗传性视网膜疾病市场，普遍观察到产品成本非常复杂，需要精确，其他规格增加了产品成本。

治疗费用高昂是由于治疗的检查点多个以及使用高科技方式进行此类治疗程序。

然而，医院护理进一步增加了莱伯先天性黑蒙症的成本。由于创新和先进产品的成本很高，治疗成本也相应上升，因此，莱伯先天性黑蒙症治疗和诊断相关的高成本预计将抑制莱伯先天性黑蒙症市场的增长。

而欧洲药品管理局则没有。基因治疗产品受 FDA 生物制品评估与研究中心 (CBER) 监管。FDA 要求在开始临床研究之前提交 IND，并提交经批准的生物制品许可申请 (BLA) 才能在美国销售该产品。基因治疗产品开发和制造的监管框架包括法规和指导文件，包括监管机构对这些管理文件的解释。

然而，每个国家都受到不同当局制定的指导方针的约束，这预计会对莱伯先天性黑蒙市场的增长构成挑战。

近期发展

2022 年 3 月，SparingVision 宣布将在视觉和眼科学研究协会 (ARVO) 2022 年年会上展示其主要候选产品 SPVN06 及其核心重点适应症视网膜色素变性的自然病史的数据。这有助于该公司展示其在管线产品方面的进展。

中东和非洲莱伯先天性黑蒙症市场差距

中东和非洲莱伯先天性黑蒙市场根据疾病类型、类型、最终用户和分销渠道分为五个显著的细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。

疾病类型

婴儿型
幼年型
其他的

根据疾病类型，莱伯先天性黑蒙症市场分为婴儿型、青少年型和其他型

类型

诊断
治疗

根据类型，莱伯先天性黑蒙市场细分为诊断和治疗。诊断部分进一步细分为临床诊断和基因诊断。临床诊断进一步细分为临床眼科检查、视野测试、零售成像和电生理测试。临床诊断细分为电生理测试、视网膜成像、视野测试和临床眼科检查。电生理测试细分为全视野视网膜电图 (ERG) 和暗适应测量 (DA)。视网膜成像细分为光学相干断层扫描 (OCT)、眼底自发荧光成像 (FAF)、扫描激光检眼镜 (SLO) 和自适应光学 (AO) 成像和传统彩色眼底成像。视野测试细分为计算机化视野测试和手动视野测试。临床检查细分为裂隙灯、间接检眼镜、屈光测试和散瞳检查。治疗领域进一步细分为基因治疗、视网膜治疗、神经保护剂和其他。基因治疗进一步细分为 luxturna 和其他。神经保护剂进一步细分为维生素 A 棕榈酸酯、二十二碳六烯酸 (DHA)、叶黄素和其他。

最终用户

医院
专科诊所
门诊手术中心
家庭医疗保健
其他的

根据最终用户，莱伯先天性黑蒙市场分为医院、专科诊所、门诊手术中心、家庭医疗保健和其他。

分销渠道

零售销售
直接招标

莱伯先天性黑蒙症市场

根据分销渠道，莱伯先天性黑蒙市场细分为零售、直接招标。

莱伯先天性黑蒙症市场区域分析/见解

对莱伯先天性黑蒙市场进行了分析，并按国家、疾病类型、类型、最终用户和分销渠道提供了市场规模洞察和趋势。

莱伯先天性黑蒙市场报告涉及的国家包括沙特阿拉伯、南非、阿联酋、以色列、科威特、埃及、中东其他地区和非洲。

由于主要参与者不断增加的战略主动性，南非有望占据主导地位。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

竞争格局和莱伯先天性黑蒙市场份额分析

中东和非洲莱伯先天性黑蒙市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、中东和非洲业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司关注的莱伯先天性黑蒙市场有关。

一些主要参与者包括 Invitae Corporation、Spark Therapeutics, Inc.、LKC Technologies、CENTOGENE NV、Optos、Metrovision、Blue Print Genetics Oy (Quest Diagnostics 的子公司)、CD Genomics、ProQR Therapeutics、OCUGEN, INC.、MeiraGTx Limited、Coave Therapeutics、IVERIC bio, Inc.、Atsena Therapeutics、Editas Medicine、Eluminex Biosciences、Okuvision、Astellas Pharma Inc.、Allergan、agtc、Gyroscope Therapeutics Limited、SparingVision、Kubota Pharmaceutical Holdings Co. Ltd.、REGENXBIO Inc. 等。

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、中东和非洲与地区和供应商份额分析。如有进一步询问，请要求分析师致电。

SKU-68125

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Request for Demo

表格列表

TABLE 1 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 2 MIDDLE EAST & AFRICA INFANTILE TYPE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA JUVENILE TYPE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA OTHERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA HOSPITALS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA SPECIALITY CLINICS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA HOME HEALTHCARE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA OTHERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA DIRECT TENDER IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 41 MIDDLE EAST AND AFRICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 42 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 43 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 44 SOUTH AFRICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 45 SOUTH AFRICA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 46 SOUTH AFRICA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 47 SOUTH AFRICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 48 SOUTH AFRICA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 SOUTH AFRICA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 50 SOUTH AFRICA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 51 SOUTH AFRICA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 52 SOUTH AFRICA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 53 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 54 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 55 SOUTH AFRICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 56 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 57 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 58 SAUDI ARABIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 59 SAUDI ARABIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 60 SAUDI ARABIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 61 SAUDI ARABIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 62 SAUDI ARABIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 63 SAUDI ARABIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 64 SAUDI ARABIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 65 SAUDI ARABIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 66 SAUDI ARABIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 67 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 68 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 69 SAUDI ARABIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 70 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 71 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 72 U.A.E THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 73 U.A.E GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 74 U.A.E NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 75 U.A.E DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 76 U.A.E CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 77 U.A.E RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 78 U.A.E ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 79 U.A.E VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 80 U.A.E CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 81 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 82 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 83 U.A.E RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 84 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 85 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 86 ISRAEL THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 87 ISRAEL GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 88 ISRAEL NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 89 ISRAEL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 90 ISRAEL CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 91 ISRAEL RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 92 ISRAEL ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 93 ISRAEL VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 94 ISRAEL CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 95 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 96 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 97 ISRAEL RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 98 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 99 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 100 EGYPT THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 101 EGYPT GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 102 EGYPT NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 103 EGYPT DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 104 EGYPT CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 105 EGYPT RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 106 EGYPT ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 107 EGYPT VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 108 EGYPT CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 109 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 110 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 111 EGYPT RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 112 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 113 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 114 KUWAIT THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 115 KUWAIT GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 116 KUWAIT NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 117 KUWAIT DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 118 KUWAIT CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 119 KUWAIT RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 120 KUWAIT ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 121 KUWAIT VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 122 KUWAIT CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 123 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 124 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 125 KUWAIT RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 126 REST OF MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

图片列表

FIGURE 1 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: END USER GRID

FIGURE 9 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: SEGMENTATION

FIGURE 11 RISING GOVERNMENT AWARENESS PROGRAMS ABOUT THE INHERITED RETINAL DISEASE IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 INFANTILE TYPE IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET IN 2022 & 2029

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FOR THE MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET

FIGURE 15 PROPORTION OF RPE65 GENE MUTATION IN CLINICALLY DIAGNOSED LCA PATIENTS

FIGURE 16 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, 2021

FIGURE 17 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, 2022-2029 (USD MILLION)

FIGURE 18 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, CAGR (2022-2029)

FIGURE 19 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 20 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, 2021

FIGURE 21 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 22 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 23 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 24 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2021

FIGURE 25 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 26 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, CAGR (2022-2029)

FIGURE 27 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, LIFELINE CURVE

FIGURE 28 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 29 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 30 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, CAGR (2022-2029)

FIGURE 31 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, LIFELINE CURVE

FIGURE 32 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: SNAPSHOT (2021)

FIGURE 33 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021)

FIGURE 34 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 35 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 36 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE (2022-2029)

FIGURE 37 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: COMPANY SHARE 2021 (%)

查看详细信息

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。

DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。

中东和非洲莱伯先天性黑蒙市场 – 行业趋势和 2029 年预测

通过敏捷供应链咨询解决关税挑战

中东和非洲莱伯先天性黑蒙症市场动态

中东和非洲莱伯先天性黑蒙症市场差距

莱伯先天性黑蒙症市场区域分析/见解

竞争格局和莱伯先天性黑蒙市场份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

报告

市场洞察

支持

解决方案

中东和非洲莱伯先天性黑蒙市场 – 行业趋势和 2029 年预测

通过敏捷供应链咨询解决关税挑战

中东和非洲莱伯先天性黑蒙症市场动态

中东和非洲莱伯先天性黑蒙症市场差距

莱伯先天性黑蒙症市场 区域分析/见解

竞争格局和莱伯先天性黑蒙市场 份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

浏览相关页面

莱伯先天性黑蒙症市场区域分析/见解

竞争格局和莱伯先天性黑蒙市场份额分析